Clinical lymphoma, myeloma & leukemia · 2025
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaedbey Rayan, Venner Christopher P, Reece Donna, Hay Kevin, Gul Engin, Su Jiandong, McCurdy Arleigh, Chu Michael P, Jimenez-Zepeda Victor H, Song Kevin, Mian Hira, Louzada Martha, Sebag Michael, Reiman Anthony, White Darrell, Stakiw Julie, Kotb Rami, Aslam Muhammad, Masih-Khan Esther, Bergstrom Debra, LeBlanc Richard
Аннотация
BACKGROUND: Salvage autologous stem cell transplantation (ASCT2) remains a treatment option for selected patients with relapsed multiple myeloma (MM). In this multicenter study, we conducted a retrospective analysis using the Canadian Myeloma Research Group (CMRG) database to evaluate real-world outcomes of ASCT2 in the maintenance era.
PATIENTS AND METHODS: Three hundred and fifty-two patients underwent ASCT2 following progression after ASCT1 between 2012 and 2021. Progression-free survival (PFS), overall survival (OS), depth of response, and the impact of maintenance therapy after ASCT2 were assessed, with further stratification based on maintenance use after ASCT1.
RESULTS: Our analysis demonstrated that post-ASCT2 maintenance therapy was associated with improved outcomes, particularly in patients who had also received maintenance after ASCT1 (25.2 months (95% CI, 20.8-39.6) versus 11.6 months (95% CI, 8.51-18.8)). In patients receiving lenalidomide maintenance after ASCT1, a remission lasting less than 3 years represented a high risk group with poor outcomes with an ASCT2.
CONCLUSION: While novel agents continue to expand treatment options, ASCT2 remains a viable therapeutic strategy in appropriately selected patients, especially those with durable responses to prior therapy.
PATIENTS AND METHODS: Three hundred and fifty-two patients underwent ASCT2 following progression after ASCT1 between 2012 and 2021. Progression-free survival (PFS), overall survival (OS), depth of response, and the impact of maintenance therapy after ASCT2 were assessed, with further stratification based on maintenance use after ASCT1.
RESULTS: Our analysis demonstrated that post-ASCT2 maintenance therapy was associated with improved outcomes, particularly in patients who had also received maintenance after ASCT1 (25.2 months (95% CI, 20.8-39.6) versus 11.6 months (95% CI, 8.51-18.8)). In patients receiving lenalidomide maintenance after ASCT1, a remission lasting less than 3 years represented a high risk group with poor outcomes with an ASCT2.
CONCLUSION: While novel agents continue to expand treatment options, ASCT2 remains a viable therapeutic strategy in appropriately selected patients, especially those with durable responses to prior therapy.